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Purpose: Although stromal-cell-derived factor (SDF)-1α is suggested to be involved in tumorigenicity and tumor angio-
genesis, the clinicopathological significance of its expression in colorectal cancers is not fully understood. We examined 
SDF-1α expression in colorectal cancers and investigated its relationship to clinicopathological features such as tumor 
staging, lymph-node metastasis, vascular invasion (VI), lymphatic invasion (LI) and neural invasion (NI). 
Methods: Specimens of 83 primary colorectal cancers were examined immunohistochemically, and the relationships be-
tween clinicopathological features and SDF-1α expression were analyzed. To compare the expressions between the normal 
colon tissue and colorectal cancer tissues, we performed Western blot analyses. 
Results: According to the Western blot analyses, SDF-1α was more highly expressed in colorectal carcinoma tissues than 
in normal colonic mucosa (20/21). According to the immunohistochemical stain, SDF-1α was associated with nodal sta-
tus, distant metastasis, tumor staging, VI and LI. SDF-1α expression had a significant prognostic value for overall survival. 
Kaplan-Meier plots of survival in patients with high SDF-1α showed that high SDF-1α expression was associated with a 
shorter overall survival. However, no association was found between SDF-1α expression and other pathologic or clinical 
variables, including age, gender, degree of differentiation, and presence of perineural invasion. 
Conclusion: The expression of SDF-1α might be associated with tumor progression in colorectal cancer. Inhibition of 
SDF-1α could be a therapeutic option in colorectal cancer patients. 
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the prognosis can become very bad, causing the 5-year survival 
rate to drop below 10% [2]. In 30 to 40% of patients, liver metas-
tases is found during the diagnosis while in from 50% of the pa-
tients, extrahepatic metastases are found in the lung, the perito-
neum, and lymph nodes [3]. 
The cause of death in patients with colorectal cancer is mostly 
uncontrollable metastatic lesions. Among them, the liver is the 
organ most frequently subjected to metastases, and if such metas-
tases occur, surgical resection is the only way to enhance the pa-
tient’s survival rate. However, in recent days, even patients with 
liver metastasis, owing to development of various treatment meth-
ods, the patient’s 5-year survival rate can be improved to 58% [4].
The process of cancer metastasis involves a sequence of several 
individual phases, and such sequential phases are all required to 
form metastatic cancers. Especially, angiogenesis around the tu-
mor cells is known to play an important role in the progression 
and the metastasis of cancer [5]. Vasculogenesis and angiogenesis 
are known to contribute to forming the vasculature of the tumor 
INTRODUCTION
Colorectal cancer is a very common malignant tumor not only in 
Korea but at the global level, and it is one of key causes of cancer-
induced death [1]. In cases of localized colon cancer, the 5-year 
survival rate is nearly 82 to 93%, but, once any metastasis incurs, 
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in malignancies and to its expansion, consequently helping the 
growth of malignancies. Also, as a mechanism of angiogenesis that 
affects the growth of a malignant tumor, stem cells or precursor 
cells of bone marrow have been verified to migrate to the tumor 
where they differentiate into endothelial cells and become involved 
in the angiogenesis of the tumor [6].
Incorporation of bone marrow cells into the vascular endothelial 
lining has been reported for Lewis lung carcinomas and lympho-
mas, mammary adenocarcinomas, and gliomas [7-9]. Direct dif-
ferentiation of stem/precursor cells is known to be important for 
revascularization after wound healing or ischemia of tissues whereas 
whether these cells have any critical roles in the vasculature expan-
sion of a tumor is still unclear [10].
Various kinds of cytokines, such as granulocyte colony-stimulat-
ing factor, placental growth factor and stromal-cell-derived factor-1 
(SDF-1), are known to cause mobility or chemotaxis of bone mar-
row stem/precursor cells, and among them, SDF-1 has a function 
to specifically control chemotaxis of cell groups that express CXCR4 
receptor, such as CD34+ stem/precursor cells [11]. SDF-1 controls 
engraftment of hematopoietic stem cells inside the bone marrow 
in the embryogenesis period or in the adult period. In addition, 
this chemokine has been known to stimulate the gathering of en-
dothelial precursor cells to ischemic areas and as a result, to con-
tribute to neovascularization [12, 13].
Recently, a fact was identified that SDF-1 chemokine and its re-
ceptor play notable roles in the onset and the progression of pri-
mary or metastatic cancer from various organs [14-16]. Many stud-
ies indicate that SDF-1α and its receptor CXCR4 play major roles 
in the formation of tumors as these substances have been identi-
fied as having very important roles in survival and proliferation, 
chemotaxis, migration and adhesion of cells [17]. The authors 
aimed to investigate the expression of SDF-1α protein in colorec-
tal cancer tissues based on the aforementioned results and to iden-
tify what kinds of roles these substances have in colorectal cancer 
by comparing the expressions of SDF-1α protein and various clin-
icopathological factors of patients with colorectal cancer. 
METHODS
Subjects 
The study included 83 patients with colon cancer on whom a rad-
ical resection of the primary tumor was performed at Soonchun-
hyang University Cheonan Hospital from January 2003 to August 
2006. Investigations addressed the ages of the patients, gender, 
stage, and distant metastasis. From pathology reports, the degree 
of differentiation, the invasion depth of the primary cancer, lymph-
node metastasis and survival rate were investigated. The clinical 
profiles of the patients were investigated in a retrospective man-
ner based on their medical records. 
The stages of disease were classified according to the tumor-node-
metastasis (TNM) staging system by using the Classification ver-
sion 7 published by the American Joint Committee on Cancer. A 
5-year follow-up was conducted to identify the survival rate.   
Western blot
Cell lysates were prepared using radioimmunoprecipitation assay 
buffer (1× phosphate-buffered saline [PBS], pH 7.2, 0.5% sodium 
deoxycholate, 1% Nonidet P-40, 0.1% sodium dodecyl sulfate). In 
this method, the protein (40 μg/lane) was isolated from NuPAGE 
4 to 12% bis-trisployacrylamide gels (Invitrogen, Carlsbad, CA, 
USA) and sent to an Immuno-Blot polyvinylidene fluoride mem-
brane by electrophoresis. Thereafter, the membranes were incu-
bated at room temperature for 1 hour by using anti-SDF-1α anti-
body (R&D Systems Inc., Minneapolis, MN, USA) in a 1:500 di-
lution. Then, a reaction was induced for horseradish-peroxidase-
conjugated secondary antibody in a 1:5,000 diluted solution while 
the signals were visualized using an enhanced chemiluminescent 
detection kit. β-actin was also studied by using the aforementioned 
procedures.
Immunohistochemical staining 
Sample tissues taken from colon cancer were fixed in 10% neutral 
buffered formalin solution and prepared using the method with 
routine use of paraffin blocks. In order to perform the immuno-
histochemical staining for SDF-1α, a 4-mm-thinck paraffin block 
was de-paraffined, re-moisturized and placed in 0.01-M citrate 
buffer solution, with subsequent heating by using ultrashort waves 
for 15 minutes. The sections were reacted with a mixture of meth-
anol and 0.3% H2O2 in methanol for 20 minutes at room temper-
ature in order to remove the intrinsic peroxidase activity. As the 
next step, the sections were immunohistochemically stained using 
an UltraTech Kit (Immunotech, Marseille, France) according to 
the instructions from the manufacturer. The sections were pre-
treated with 1% bovine serum albumin in PBS and were reacted 
to anti-SDF-1α antibody (dilution 1:50; R&D Systems Inc.) for 1 
hour at room temperature. Thereafter, the sections were reacted 
to biotinylate secondary antibody for 15 minutes, washed with 
PBS, and treated with peroxidase-conjugated streptavidin for 20 
minutes. Finally, the sections were reacted to 3, 30-diaminobenzi-
dine tetrahydrochloride containing 0.05% H2O2 for 3 minutes and 
counterstained with hematoxylin. Sections of esophageal cancer 
identified with excessive expression of protein were used as the 
positive control group, but were not applied to the negative con-
trol group. 
Evaluation of immunohistochemical staining
In the immunohistochemical staining using SDF-1α antibody, de-
pending on the intensity of staining on the cytoplasm of SDF-1α, 
the expression was classified by reading into 2 groups: weak ex-
pression and strong expression. The intensity of staining was into 
strong positive (3+), weak positive (1+), and negative (0). 0 and 
1+ were determined as weakly expressed while 2+ and 3+ were 
determined as strongly expressed. The readings were carried out 
by two specialized pathologists, each of whom generated respec-Journal of The Korean Society of
Coloproctology
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tive reading results, and if they had different results for one read-
ing, they consulted to derive one conclusion.
Statistical analysis 
The statistical analysis was performed using SPSS ver. 17.0.1 (SPSS 
Inc., Chicago, IL, USA). In the data analysis, the chi-square test 
was used to analyze the correlation between SDF-1α and clinico-
pathological factors such as the intensity of SDF-1α staining, the 
gender, the age, the stage of disease (pTNM) and the degree of 
differentiation on the final biopsy report, as well as the presences 
of vascular invasion, lymphatic invasion and neural invasion. The 
survival rate was analyzed using the Kaplan-Meier method and 
was subsequently assessed by using the log-rank test. 
RESULTS
Clinical characteristics
The mean age of the 83 patients with colorectal cancer was 61 years 
(range, 20 to 82 years) old. By gender, 37 (44.6%) were male, and 
46 (55.4%) were female. By the stage of disease, 9 (10.8%) were at 
stage I, 25 (30.1%) were at stage II, 44 (53.1%) were at stage III and 
5 (6.0%) were at stage IV. By the T stage, 3 (3.6%) were T1, 7 (8.4%) 
were T2, 69 (83.1%) were T3 and 4 (4.8%) were T4. The number 
of negative lymph-node metastases was 32 (38.6%); N1 was 27 
(32.5%), and N2 was 24 (28.9%) (Table 1).
Results of Western blot 
When Western blot tests were performed using the normal colonic 
mucosa and colorectal cancer tissues, it was possible to observe 
that SDF-1α was more highly expressed in the colorectal cancer 
tissues in 20 cases out of 21 cases (Fig. 1).
Immunohistochemical results of SDF-1α 
When the immunohistochemical staining was performed on 
SDF-1α by using paraffin-embeddedcolorectal cancer tissues (Fig. 
2), out of 83 subjects, the number of cases with no expression of 
SDF-1α (normal, negative) was 4 (4.8%), that of weak expression 
(1+) was 22 (26.5%), thatof moderate expression (2+) was 19 
(22.9%), and that of strong expression (3+) was 38 (45.8%). When 
the unstained cases and the patients with weak response to stain-
ing were categorized as the weak positive group and the patients 
with moderate and strong staining were categorized as the strong 
positive group, the former had 26 subjects (31.1%), and the latter 
had 57 subjects (68.9%) (Table 2).
Correlation between SDF-1α expression and 
clinicopathological factors  
When the correlations between the intensity of SDF-1α staining 
and several clinical parameters were analyzed, the results showed 
that the degree of T staging and the differentiation of cancer tis-
sues had no statistically significance correlation with the expres-
sion of SDF-1α. Nevertheless, among the 57 patients in the group 
with strong expression of SDF-1α, lymph-node metastasis was pres-
ent in 44 cases (77.1%), and among the 26 patients in the group 
Table 1. Patients characteristics
Characteristic No. of cases (%)
Sex
   Female 46 (55.4)
   Male 37 (44.6)
Age
   <60 35 (42.2)
   ≥60 48 (57.8)
T stage
   T1 3 (3.6)
   T2 7 (8.4)
   T3 69 (83.1)
   T4 4 (4.8)
Nodal status
   N0 32 (38.6)
   N1 27 (32.5)
   N2 24 (28.9)
Stage
   I 9 (10.8)
   II 25 (30.1)
   III 44 (53.1)
   IV 5 (6.0)
SDF-1 (9 kDa)
SDF-1 (9 kDa)
N  T  N  T  N  T  N  T  N  T
N  T  N  T  N  T  N  T  N  T
N  T  N  T  N  T  N  T  N  T
N  T  N  T  N  T  N  T  N  T
β-Actin (42 kDa)
β-Actin (42 kDa)
Fig. 1. Expression of stromal-cell-derived factor (SDF)-1α in malignant and non-malignant colorectal tissues. N, normal tissues; T, cancer tissues.Journal of The Korean Society of
Coloproctology
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with weak expression of SDF-1α, lymph-node metastasis was pres-
ent in 19 cases (73.1%), indicating a high level of correlation be-
tween SDF-1α expression and lymph-node metastasis (P = 0.001). 
In addition, distant metastasis of colorectal cancer and TNM stage 
were related to the expression SDF-1α (P = 0.007, P = 0.001).
When the relations with vascular invasion, lymphatic invasion 
and neural invasion were analyzed, all 11 patients who had shown 
vascular invasion presented a clinical profile with strong expres-
sion of SDF-1α (P = 0.015). Out of the 18 patients with the pres-
ence of lymphatic invasion, 16 patients (89%) had shown an ex-
pression of SDF-1α, a statistically significant result (P = 0.025). 
However, neural invasion of cancer cells did not show any signifi-
cant relation with the expression of SDF-1α (Table 2).
Relation between the expression of SDF-1α and the prognosis   
The relation between the expression of SDF-1α and the survival 
rate was analyzed using follow-up observations, outpatient visits 
and phone calls for up to 60 months post-operatively, as a method 
to check on the survival of the 83 patients. The group of patients 
with strong expression of SDF-1α on the Kaplan-Meier’s Survival 
curve showed poorer survival rate than the patient group with 
weak expression of SDF-1α, suggesting that the expression of 
SDF-1α is relevant to the prognosis (P = 0.021) (Fig. 3). 
DISCUSSION
Several studies so far have reported on the role of chemokine 
SDF-1α/CXCR4 as a signal transduction pathway. Those studies 
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Fig. 3. Kaplan-Meier survival curves for weak and strong stromal-cell-
derived factor (SDF)-1α expression in cases of colorectal cancer.
Fig. 2. Immunohistochemistry for stromal-cell-derived factor-1α in the normal colon and 
in colorectal cancer tissues (×400): (A) negative immunoreactivity, (B) weak immunoreac-
tivity (1+) in the cytoplasm, (C) moderate-type (2+): immunoreactivity moderately detected 
in the cytoplasm of cancer cells, and (D) strong-type (3+): immunoreactivity strongly de-
tected in the cytoplasm of cancer cells.  D
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and human immunodeficiency virus (HIV) infection. In 2001, 
Müller et al. [18] reported that SDF-1α was expressed from spots 
such as lymph nodes or bone marrow and in organs such as the 
Table 2. Stromal-cell-derived factor (SDF)-1α expression and the demographics
Variable Patient
SDF-1α staining pattern
P-value
Low High
Sex 0.143
   Male 46  16 (34.8) 30 (65.2)
   Female 37  10 (27.0) 27 (73.0)
Age (yr) 0.171
   <60 35 10 (28.6) 25 (71.4)
   ≥60 48 16 (33.3) 32 (66.7)
T stage 0.109
   T1   3 2 (66.7) 1 (33.3)
   T2   7 4 (57.1) 3 (42.9)
   T3 69 20 (29.0) 49 (71.0)
   T4   4  0 (0.0) 4 (100)
Nodal status 0.001
   N0 32 19 (59.4) 13 (40.6)
   N1 27 5 (18.5) 22 (71.5)
   N2 24 2 (8.3) 22 (91.7)
Distant metastasis 0.007
   M0 50 21 (42.0) 29 (58.0)
   M1 33 5 (15.2) 28 (84.8)
Stage 0.001
   I   9 7 (77.8) 2 (22.2)
   II 25 13 (52.0) 12 (48.0)
   III 44 6 (13.6) 38 (86.4)
   IV   5 0 (0) 5 (100)
Differentiation 0.151
   Well   3 2 (66.7) 1 (33.3)
   Moderate 72 24 (33.3) 48 (66.7)
   Poor   4 0 (0) 4 (100)
   Mucinous   4  0 (0) 4 (100)
Vascular invasion 0.015
   Yes 11 0 (0) 11 (100)
   No 72 26 (36.1) 46 (63.9)
Lymphatic invasion 0.025
   Yes 18 2 (11.1) 16 (88.9)
   No 65 24 (36.9) 41 (63.1)
Neural invasion 0.687
   Yes   1 0 (0) 1 (100)
   No 82 26 (31.7) 56 (68.3)
were carried out in the areas of immunology and infection mainly; 
in addition, some studies addressed the roles of this ligand and its 
receptor in the areas of hepatopoiesis, migration of lymphocytes Journal of The Korean Society of
Coloproctology
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lung, where metastasis of breast cancer frequently occurs, but it 
was not expressed easily in the kidney where such metastasis rarely 
occurs. Thereafter, because of various studies and reports, together 
with continuous reports on the ligand of such a pathway, SDF-1α 
being associated with neovascularization in malignant tumors 
and affecting the progression of tumors, the pathway of SDF-1α/
CXCR4 in malignant tumors began to attract interest. 
Currently there are more than 50 chemokines, and all of them 
have 4 conserved cysteinyl groups with the formation of 2 essen-
tial disulphide bonds. In the beginning, this topic attracted clinical 
interest in diseases such as HIV/acquired immune deficiency syn-
drome or in the field of immunology mainly, but it has become a 
subject of interest as the pathways of these chemokines have be-
come material to the treatment of cancer in recent days. Among 
them, a chemokine being noted with interest as the target of can-
cer treatment in recent days is SDF-1α, which is also called CXCL12. 
This chemokine begins signal transduction as coupling to recep-
tors CXCR4 and CXCR7, which have the same nature [19].
SDF-1α is a specific ligand to CXCR4. yet SDF-1α can couple 
with the CXCR7 receptor. When the intra-cell molecular and phys-
iological variations caused by the coupling with the CXCR4 recep-
tor were investigated, which is a general coupling pattern with 
SDF-1α, SDF-1α was found to couple with CXCR4 and to activate 
the pathway of extracellular signal-regulated kinase 1/2, i.e., the 
phosphatidylinositol 3-kinase and mitogen-activated protein ki-
nase pathway, such as protein kinase (B-kinase), that internalizes 
the flow of calcium that is being facilitated by CXCR4 inside a cell 
and that is involved in the migration, proliferation, fragmentation 
and survival of cells [20]. 
CXCR4 helps the interaction between cancer cells and endothe-
lial cells by activating either the rolling of cancer cells or the endo-
thelial cell migration of cancer cells [21]. In addition, SDF-1α is 
considered as controlling the intra-tissue localization of cancer 
cells and having direct effects on the migration of cancer cells, re-
sulting in an induction of metastasis [22]. Strieter et al. [22] re-
ported from an in vitro study on a non-small cell lung cancer cell 
line that cancer cells migrated along the chemotactic gradient of 
SDF-1α/CXCR4. The authors in this study investigated the rela-
tions between several clinicopathological factors of patients with 
colon cancer, especially those between lymph-node metastasis of 
colorectal cancer cells and the expression of SDF-1α in order to 
identify the role of SDF-1α in colorectal cancer, which has such 
molecular and physiological actions. They also investigated the 
relations through immunohistochemical staining of SDF-1α in 
primary colorectal cancer tissues in order to identify the effects of 
the presence of SDF-1α expression on the prognosis for the pa-
tient. In addition, they performed a comparative investigation by 
conducting Western blot tests in order to compare the expression 
of SDF-1α protein in colorectal cancer cells with that in normal 
colorectal tissues. There had been reports from studies on the ex-
pression of SDF-1α in cancer cells that the prognosis of patients 
and the expression of SDF-1α had shown significant relevance in 
neuroglioma and gastric cancer cells, but that was not the case for 
epithelial ovarian cancer cells or oral epidermoid carcinoma cells 
[23-26]. However, it should be noted that there have not been 
many reports so far.   
The fact that the role of SDF-1α in the progression of malignant 
tumor is related to neovascularization in tumors has been identi-
fied in several study results. Both SDF-1α and its receptor are ex-
pressed from vascular endothelial cells, and SDF-1α plays an im-
portant role in gathering various bone marrow-originating CXCR4-
expressing cells around the tumor, such as CD11b + myelomono-
cyte or endothelial precursor cells [27]. On the other hand, the 
activations of vascular endothelial growth factor (VEGF), placenta 
growth factor (PlGF), VEGF receptor 1 (VEGFR1) and hypoxia 
inducible factor 1 alpha (HIF-1α), which triggers expression of 
SDF-1α locally in and around the tumor, promote recruitment of 
various cells originating from bone marrow through the CXCR4 
pathway [28].
Consequently, by recruiting endothelial precursor cells originat-
ing from the bone marrow, which express the SDF-1α receptor, 
that is, the CXCR4 chemokine, around the tumor through SDF-1α 
expressed from tumor tissues through such processes, this ligand 
and receptor pathway becomes involved in neovascularization 
around the tumor. Although SDF-1α expression in the colorectal 
cancer cell line has been described in a few of previous studies, 
the pathological role of the SDF-1α/CXCR4 axis, which is involved 
in the progression of colorectal cancer, in regard to its molecular 
mechanism is still unidentified. In addition, not many studies have 
addressed the expression of this cytokine in human colorectal can-
cer tissues so far; as a matter of fact, the authors’ study is consid-
ered as being significant because of its great emphasis on SDF-1α 
expression in human colorectal cancer tissues. 
Moreover, in the study of the authors, not only the relevance of 
the expression of SDF-1α to lymphatic invasion, venous invasion 
and lymphatic metastasis presented in patients with colorectal can-
cer but also the relevance to the survival rate of patients are said to 
have very important significance. However, unlike the results re-
ported by the authors, results based on Northern blot tests have 
shown that mRNA expression of SDF-1α is reduced in colorectal 
cancer tissues more than it is in normal colorectal tissues [29]. 
The study results derived by the authors demonstrate that a close 
relationship exists between the expression of SDF-1α and the lymph-
node metastasis of colorectal cancer and that such expression of 
chemokine in colorectal cancer is important not only for control-
ling deterioration of colorectal cancer but also for playing an im-
portant role in lymph-node metastasis. Furthermore, the study 
result of authors showed that the presence of SDF-1α expression 
affected the prognosis of patients with colorectal cancer and that 
patients with increased protein expressions of SDF-1α demon-
strated lower rates of 5-year survival than patients with less ex-
pression; thus, such protein expression of SDF-1α could affect the 
survival rate of patients. Also, expression of SDF-1α was shown to 
be higher in most colorectal cancer tissues than in normal colorec-Journal of The Korean Society of
Coloproctology
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tal tissues through a comparison of the SDF-1α expressions in both 
tissues. 
In the study of authors, it was possible to identify the clinical sig-
nificance of SDF-1α expression in primary colorectal cancer tis-
sues. This was a result of an investigation on the protein expres-
sion of SDF-1α, that is, a ligand of this signal transduction path-
way from the primary colorectal cancer tissues, which had shown 
that the expression of SDF-1α was related to the lymph-node me-
tastasis of colorectal cancer and that such expression was related 
to the prognosis for the patient. However, the study failed to estab-
lish the fact that the angiogenesis was associated with the expres-
sion of SDF-1α in colorectal cancer. Therefore, such an association 
should be verified in a future study.
In conclusion, from the result of this study, it was possible to iden-
tify that the expression of SDF-1α was involved in colorectal-can-
cer-activated lymph-node metastasis of cancer cells and that it was 
involved in the progression of colorectal cancer. In addition, the 
expression of SDF-1α is related to the survival rate of patients with 
colorectal cancer, so this molecule can be a target of colorectal can-
cer treatment and can be used as a prognostic factor for colorectal 
cancer patients. The study results of the authors establish that the 
SDF-1α chemokine can play roles as a tumor marker of lymph-
node metastasis in colorectal cancer and as a mediator for expan-
sion of the tumor; nonetheless, further studies on what roles SDF-1α 
may play in the metastasis of colorectal cancer and in angiogene-
sis are thought to be necessary.
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